Drug details

Luxturna (voretigene neparvovec-rzyl intraocular suspension for injection)

type of Retinal Gene Therapies

Luxturna (voretigene neparvovec-rzyl) is an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65mutation-associated retinal dystrophy.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• headache,
• eye pain or swelling,
• seeing halos around lights,
• increased sensitivity to light,
• retinal detachment,
• new or worsening cataract (clouding of the lens inside of the eye),
• thinning of the clear layer in front of your eye,
• deposits under your retina,
• separating layers of a developing hole in the center of your retina,
• thinning of the retina or loss of function,
• breaks or wrinkling on the surface of your retina,
• bleeding in the retina,
• permanent decline in the sharpness of your vision,
• new or worsening vision problems,
• flashes of light or “floaters” in your vision,
• crusting or drainage from the eye, and
• vision loss